TBC1 domain family member 8BGenealiases: GRAMD8B · NPHS20
Q-omics provides the consensus-scored TBC1D8B profile across patient tissues and cancer cell-line models. TBC1D8B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TBC1D8B is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TBC1D8B RNA expression shows 19,423 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where TBC1D8B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D8B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D8B survival associations across molecular data types. TBC1D8B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D8B RNA expression–survival associations across cancer types. High TBC1D8B expression shows unfavorable associations in UCEC, LGG, UVM and BLCA, but favorable associations in KIRC and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TBC1D8B RNA expression.
This table summarizes TBC1D8B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TBC1D8B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D8B shows lower tumor expression in KICH, THCA and UCEC and higher tumor expression in HNSC, KIRC and STAD. The HNSC box plot shows higher TBC1D8B RNA expression in tumor versus normal tissue (log2 FC = +0.804, t-test p < 0.001).
This table shows molecular features associated with TBC1D8B in patient tissues and cancer cell lines. In patient samples, TBC1D8B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D8B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
